Market Overview

Pseudomonas Aeruginosa Infections Pipeline Review, H2 2018 -


The "Pseudomonas
aeruginosa Infections - Pipeline Review, H2 2018"
pipelines has been added to's

Pseudomonas aeruginosa Infections - Pipeline Review, H2 2018, provides
comprehensive information on the therapeutics under development for
Pseudomonas aeruginosa Infections (Infectious Disease), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Pseudomonas aeruginosa Infections (Infectious Disease) pipeline
guide also reviews of key players involved in therapeutic development
for Pseudomonas aeruginosa Infections and features dormant and
discontinued projects. The guide covers therapeutics under Development
by Companies /Universities /Institutes, the molecules developed by
Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I,
Preclinical, Discovery and Unknown stages are 1, 3, 2, 7, 71, 22 and 1
respectively. Similarly, the Universities portfolio in Preclinical,
Discovery and Unknown stages comprises 15, 15 and 1 molecules,

Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide
helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to
create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Pseudomonas aeruginosa Infections - Overview
  3. Pseudomonas aeruginosa Infections - Therapeutics Development
  4. Pseudomonas aeruginosa Infections - Therapeutics Assessment
  5. Pseudomonas aeruginosa Infections - Companies Involved in Therapeutics
  6. Pseudomonas aeruginosa Infections - Drug Profiles
  7. Pseudomonas aeruginosa Infections - Dormant Projects
  8. Pseudomonas aeruginosa Infections - Discontinued Products
  9. Pseudomonas aeruginosa Infections - Product Development Milestones
  10. Appendix

Companies Mentioned

  • Achaogen Inc
  • Acies Bio doo
  • Aeolus Pharmaceuticals Inc
  • AiCuris GmbH & Co KG
  • AlgiPharma AS
  • AmpliPhi Biosciences Corp
  • Appili Therapeutics Inc
  • Aridis Pharmaceuticals Inc
  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • Destiny Pharma Plc
  • Evaxion Biotech ApS
  • Evotec AG
  • F. Hoffmann-La Roche Ltd
  • Helix BioMedix Inc
  • Inhibrx LP
  • Insmed Inc
  • KBP BioSciences Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Lakewood-Amedex Inc
  • LegoChem Biosciences Inc
  • Meiji Seika Pharma Co Ltd
  • Melinta Therapeutics Inc
  • Microbiotix Inc
  • Nosopharm SAS
  • Novabiotics Ltd
  • Novartis AG
  • Peptilogics Inc
  • Pfizer Inc
  • Pherecydes Pharma SA
  • Phico Therapeutics Ltd
  • Redx Pharma Plc
  • Sealife PHARMA GMBH
  • Visterra Inc
  • Wockhardt Ltd

For more information about this drug pipelines report visit

View Comments and Join the Discussion!